EMEA-002915-PIP01-20
Key facts
| Active substance |
SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0201/2021
|
| PIP number |
EMEA-002915-PIP01-20
|
| Pharmaceutical form(s) |
Solution and emulsion for emulsion for injection
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Sanofi pasteur
E-mail: contact-us@sanofi.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|